8-K: Philip Morris International Raises 2026 EPS Forecast on Currency

Philip Morris International announced it is raising its 2026 full-year reported diluted EPS forecast to $7.28-$7.43, driven by currency adjustments, while maintaining its adjusted diluted EPS guidance.

Summary

• Philip Morris International (PMI) is participating in the 2026 Barclays Global Consumer Conference.
• The company is raising its 2026 full-year reported diluted Earnings Per Share (EPS) forecast to a range of $7.28 to $7.43, solely to reflect currency fluctuations.
• The adjusted diluted EPS forecast remains between $8.35 to $8.50, representing a projected increase of 10.7% to 12.7% compared to 2025.
• Excluding favorable currency impacts, the adjusted diluted EPS growth is projected at 7.5% to 9.5%.
• The Q3 adjusted diluted EPS forecast has also been updated for currency, now including a 1-cent favorable impact.
• All other forecast assumptions remain unchanged from previous communications.
• PMI continues to invest in developing and commercializing smoke-free products, with over 43 million users globally as of December 31, 2025.
• The smoke-free business accounted for approximately 42% of PMI's second-quarter 2026 total net revenues.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with the company raising its full-year EPS forecast, albeit solely due to currency fluctuations, indicating a stable operational outlook.

Positives

• Raised 2026 full-year reported diluted EPS forecast to $7.28-$7.43.
• Projected adjusted diluted EPS growth of 10.7% to 12.7% for 2026 compared to 2025.
• Smoke-free products are used by over 43 million legal-age consumers globally.
• Smoke-free business accounted for 42% of Q2 2026 net revenues.
• FDA has authorized marketing for Swedish Match's General snus, ZYN nicotine pouches, and versions of PMI's IQOS devices and consumables.
• Several PMI products have obtained Modified Risk Tobacco Product authorizations from the FDA.

Negatives

• The EPS forecast increase is solely attributed to currency fluctuations, not operational improvements.
• The adjusted diluted EPS growth, excluding currency, is projected at a lower 7.5% to 9.5%.

Risks

• Marketing and regulatory restrictions could reduce competitiveness or disrupt commercialization efforts.
• Excise tax increases and discriminatory tax structures.
• Health concerns related to tobacco and nicotine products.
• Litigation related to tobacco/nicotine products and intellectual property.
• Intense competition and inability to anticipate changes in consumer preferences.
• Adverse global and country-specific economic, regulatory, and political developments.
• Geopolitical instability and the impact of Russia's invasion of Ukraine.
• Continued decline of tax-paid cigarettes and lost revenues from counterfeiting/contraband.

Future Outlook

The company has raised its 2026 full-year reported diluted EPS forecast to $7.28-$7.43 due to currency effects. The adjusted diluted EPS forecast remains $8.35-$8.50, indicating projected growth of 10.7%-12.7% over 2025, or 7.5%-9.5% excluding currency impacts. The Q3 adjusted diluted EPS forecast has also been adjusted for currency.

Management Comments

• Jacek Olczak, Group CEO PMI, will address investors at the 2026 Barclays Global Consumer Conference.
• PMI raises its 2026 full-year reported diluted EPS forecast to a range of $7.28 to $7.43 to reflect currency only.
• The forecast range for adjusted diluted EPS of $8.35 to $8.50 represents a projected increase of 10.7% to 12.7% versus $7.54 in 2025.

Industry Context

StockSavvy.ai notes that PMI's focus on raising EPS guidance, even if currency-driven, signals confidence in its financial performance amidst a challenging consumer goods landscape. The continued growth and significant revenue contribution from smoke-free products align with the broader industry trend of transitioning away from traditional cigarettes, a strategy also pursued by competitors.

Legal Proceedings

• Litigation related to tobacco and/or nicotine products and intellectual property rights.
• Governmental investigations.
• Egypt sales tax settlement adjustment mentioned as a 2025 adjustment.

Stakeholder Impact

• Shareholders: Potential for increased EPS, though driven by currency, may influence investment decisions.
• Consumers: Continued availability and development of smoke-free alternatives.
• Employees: Ongoing investment in innovation and global talent retention.
• Regulators: Subject to various marketing, tax, and product regulations globally.

Next Steps

• Continue to develop, scientifically substantiate, and commercialize innovative smoke-free products.
• Expand into wellness areas leveraging life sciences expertise.
• Monitor and adapt to evolving regulatory and market conditions.
• Integrate and realize expected benefits from recent transactions and acquisitions.

Key Dates

Recommendation

The company is raising its reported EPS forecast, which is positive, but the increase is solely due to currency, not operational improvements. The core adjusted EPS guidance remains stable, indicating expected performance. While the transition to smoke-free products is a long-term positive, the reliance on currency for short-term EPS boosts and the inherent risks in the tobacco/nicotine industry warrant a cautious 'hold' stance.

Keywords

EPS forecast, Barclays Global Consumer Conference, Philip Morris International, smoke-free products, currency impact, diluted EPS, investor webcast, regulatory